Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Soligenix Inc. has published new data showing its ebolavirus vaccines maintain full potency after two years of storage at temperatures up to 40°C (104°F). The bivalent and trivalent vaccines, developed using the company's ThermoVax platform, incorporate antigens from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus. This breakthrough addresses one of the most significant challenges in global vaccine distribution—the cold-chain requirement that limits accessibility in resource-constrained regions.
The research, conducted in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, demonstrates that protein subunit vaccines enhanced with ThermoVax technology can withstand extreme temperature conditions while maintaining efficacy. Animal studies showed robust immune responses and up to 100% protection in non-human primates, indicating the vaccines' potential effectiveness in human populations. The manuscript detailing these findings has been accepted for publication in the journal Vaccine.
The implications for global health security are substantial. Traditional vaccines require strict temperature-controlled storage and transportation, creating logistical barriers and increasing costs, particularly in developing countries and during outbreak responses. By eliminating cold-chain requirements, ThermoVax-enhanced vaccines could dramatically improve vaccine accessibility and distribution efficiency. This technology represents a critical advancement in pandemic preparedness, especially for filoviruses like Ebola that have caused devastating outbreaks in regions with limited healthcare infrastructure.
Soligenix's achievement with thermostable vaccines comes at a time when global health organizations are prioritizing technologies that can enhance rapid response capabilities. The ability to stockpile vaccines without refrigeration constraints could transform how public health agencies prepare for and respond to infectious disease emergencies. Additional information about the company's vaccine development programs is available at https://ibn.fm/SNGX.
The ThermoVax platform's success with ebolavirus vaccines suggests potential applications for other temperature-sensitive biologics. As the world continues to face emerging infectious disease threats, technologies that improve vaccine stability and distribution could play a crucial role in preventing future pandemics. This development represents a significant step toward making life-saving vaccines more accessible worldwide, particularly in regions most vulnerable to infectious disease outbreaks.